Hydroxyethyl starch and its derivatives as nanocarriers for delivery of diagnostic and therapeutic agents towards cancers

doi:10.3877/cma.j.issn.2096-112X.2020.01.005

Biomaterials Translational ›› 2020, Vol. 1 ›› Issue (1): 46-57.doi: 10.3877/cma.j.issn.2096-112X.2020.01.005

• REVIEW • Previous Articles Next Articles

Hydroxyethyl starch and its derivatives as nanocarriers for delivery of diagnostic and therapeutic agents towards cancers

Ronghua Tan, Ying Wan^*(), Xiangliang Yang^*()

National Engineering Research Centre for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.

Received:2020-08-01 Revised:2020-09-02 Accepted:2020-09-11 Online:2020-12-28 Published:2020-12-28
Contact: Ying Wan,Xiangliang Yang E-mail:ying_wan@hust.edu.cn;yangxl@hust.edu.cn

Abstract

Abstract:

Many types of drugs and agents used for cancer diagnosis and therapy often have low bioavailability and insufficient efficacy, as well as causing various side effects due to their nonspecific delivery. Nanocarriers with purposely-designed compositions and structures have shown varying degrees of abilities to deliver these compounds towards cancers in passive or active manners. Despite the availability of a variety of materials for the construction of nanocarriers, natural polymers with good biocompatibility and biodegradability are preferable for such usage because of their high in vivo safety as well as easy removal of degradation products. Among the natural polymers intended for building nanocarriers, hydroxyethyl starch and its derivatives have gained tremendous attention in the field of drug delivery in the form of nanomedicines over the last decade. There is growing optimism that ever more hydroxyethyl starch-based nanomedicines will be a significant addition to the armoury currently used for cancer diagnosis and therapy.

Key words: anticancer treatment, chemical modification, diagnostic and therapeutic agents, hydroxyethyl starch, nanocarriers, prodrug

1.	Aslam, M.; Naveed, S.; Ahmed, A.; Abbas, Z.; Gull, I.; Athar, M. Side effects of chemotherapy in cancer patients and evaluation of patients opinion about starvation based differential chemotherapy. J Cancer Ther. 2014,5, 817-822. doi: 10.4236/jct.2014.58089 URL
2.	Volk-Draper, L.; Hall, K.; Griggs, C.; Rajput, S.; Kohio, P.; DeNardo, D.; Ran, S. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res. 2014,74, 5421-5434. doi: 10.1158/0008-5472.CAN-14-0067 URL pmid: 25274031
3.	Wang, A. Z.; Langer, R.; Farokhzad, O. C. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012,63, 185-198. doi: 10.1146/annurev-med-040210-162544 URL pmid: 21888516
4.	Fang, R.; Liu, M.; Jiang, L. Design of nanoparticle systems by controllable assembly and temporal/spatial regulation. Adv Funct Mater. 2020,30, 1903351. doi: 10.1002/adfm.v30.2 URL
5.	Harada, A.; Kataoka, K. Supramolecular assemblies of block copolymers in aqueous media as nanocontainers relevant to biological applications. Prog Polym Sci. 2006,31, 949-982. doi: 10.1016/j.progpolymsci.2006.09.004 URL
6.	Tao, R.; Gao, M.; Liu, F.; Guo, X.; Fan, A.; Ding, D.; Kong, D.; Wang, Z.; Zhao, Y. Alleviating the liver toxicity of chemotherapy via ph-responsive hepatoprotective prodrug micelles. ACS Appl Mater Interfaces. 2018,10, 21836-21846. doi: 10.1021/acsami.8b04192 URL pmid: 29897226
7.	Wang, Y.; Wang, X.; Deng, F.; Zheng, N.; Liang, Y.; Zhang, H.; He, B.; Dai, W.; Wang, X.; Zhang, Q. The effect of linkers on the self-assembling and anti-tumor efficacy of disulfide-linked doxorubicin drug-drug conjugate nanoparticles. J Control Release. 2018,279, 136-146. doi: 10.1016/j.jconrel.2018.04.019 URL pmid: 29655991
8.	An, X.; Zhu, A.; Luo, H.; Ke, H.; Chen, H.; Zhao, Y. Rational design of multi-stimuli-responsive nanoparticles for precise cancer therapy. ACS Nano. 2016,10, 5947-5958. doi: 10.1021/acsnano.6b01296 URL pmid: 27285378
9.	Meng, X.; Gao, M.; Deng, J.; Lu, D.; Fan, A.; Ding, D.; Kong, D.; Wang, Z.; Zhao, Y. Self-immolative micellar drug delivery: The linker matters. Nano Res. 2018,11, 6177-6189. doi: 10.1007/s12274-018-2134-5 URL
10.	Blanco, E.; Shen, H.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015,33, 941-951. doi: 10.1038/nbt.3330 URL pmid: 26348965
11.	Deng, C.; Jiang, Y.; Cheng, R.; Meng, F.; Zhong, Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, progress and prospects. Nano Today. 2012,7, 467-480. doi: 10.1016/j.nantod.2012.08.005 URL
12.	Liu, Z.; Jiao, Y.; Wang, Y.; Zhou, C.; Zhang, Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008,60, 1650-1662. doi: 10.1016/j.addr.2008.09.001 URL pmid: 18848591
13.	Goodarzi, N.; Varshochian, R.; Kamalinia, G.; Atyabi, F.; Dinarvand, R. A review of polysaccharide cytotoxic drug conjugates for cancer therapy. Carbohydr Polym. 2013,92, 1280-1293. doi: 10.1016/j.carbpol.2012.10.036 URL pmid: 23399156
14.	Westphal, M.; James, M. F.; Kozek-Langenecker, S.; Stocker, R.; Guidet, B.; Van Aken, H. Hydroxyethyl starches: different products--different effects. Anesthesiology. 2009,111, 187-202. doi: 10.1097/ALN.0b013e3181a7ec82 URL pmid: 19512862
15.	Li, D.; Ding, J.; Zhuang, X.; Chen, L.; Chen, X. Drug binding rate regulates the properties of polysaccharide prodrugs. J Mater Chem B. 2016,4, 5167-5177. doi: 10.1039/c6tb00991c URL pmid: 32263515
16.	Paleos, C. M.; Sideratou, Z.; Tsiourvas, D. Drug delivery systems based on hydroxyethyl starch. Bioconjug Chem. 2017,28, 1611-1624. doi: 10.1021/acs.bioconjchem.7b00186 URL pmid: 28431209
17.	Goszczyński, T. M.; Filip-Psurska, B.; Kempińska, K.; Wietrzyk, J.; Boratyński, J. Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy. Pharmacol Res Perspect. 2014,2, e00047. doi: 10.1002/prp2.47 URL pmid: 25505592
18.	Xie, F.; Pollet, E.; Halley, P. J.; Avérous, L. Starch-based nano-biocomposites. Prog Polym Sci. 2013,38, 1590-1628. doi: 10.1016/j.progpolymsci.2013.05.002 URL
19.	Chen, Q.; Yu, H.; Wang, L.; ul Abdin, Z.; Chen, Y.; Wang, J.; Zhou, W.; Yang, X.; Khan, R. U.; Zhang, H.; Chen, X. Recent progress in chemical modification of starch and its applications. RSC Adv. 2015,5, 67459-67474. doi: 10.1039/C5RA10849G URL
20.	Glover, P. A.; Rudloff, E.; Kirby, R. Hydroxyethyl starch: a review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use. J Vet Emerg Crit Care (San Antonio). 2014,24, 642-661.
21.	Li, W.; Xiao, X.; Zhang, W.; Zheng, J.; Luo, Q.; Ouyang, S.; Zhang, G. Compositional, morphological, structural and physicochemical properties of starches from seven naked barley cultivars grown in China. Food Res Int. 2014,58, 7-14. doi: 10.1016/j.foodres.2014.01.053 URL
22.	Ai, Y.; Jane, J. L. Gelatinization and rheological properties of starch. Starke. 2015,67, 213-224. doi: 10.1002/star.201400201 URL
23.	Gosch, C. I.; Haase, T.; Wolf, B. A.; Kulicke, W. M. Molar mass distribution and size of hydroxyethyl starch fractions obtained by continuous polymer fractionation. Starke. 2002,54, 375-384.
24.	Boldt, J. Modern rapidly degradable hydroxyethyl starches: current concepts. Anesth Analg. 2009,108, 1574-1582. doi: 10.1213/ane.0b013e31819e9e6c URL pmid: 19372338
25.	Metcalf, W.; Papadopoulos, A.; Tufaro, R.; Barth, A. A clinical physiologic study of hydroxyethyl starch. Surg Gynecol Obstet. 1970,131, 255-267. URL pmid: 5433843
26.	Besheer, A.; Hause, G.; Kressler, J.; Mäder, K. Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. Biomacromolecules. 2007,8, 359-367. URL pmid: 17256901
27.	Yu, C.; Zhou, Q.; Xiao, F.; Li, Y.; Hu, H.; Wan, Y.; Li, Z.; Yang, X. Enhancing doxorubicin delivery toward tumor by hydroxyethyl starch-g-polylactide partner nanocarriers. ACS Appl Mater Interfaces. 2017,9, 10481-10493. doi: 10.1021/acsami.7b00048 URL pmid: 28266842
28.	Li, Y.; Wu, Y.; Chen, J.; Wan, J.; Xiao, C.; Guan, J.; Song, X.; Li, S.; Zhang, M.; Cui, H.; Li, T.; Yang, X.; Li, Z.; Yang, X. A simple glutathione-responsive turn-on theranostic nanoparticle for dual-modal imaging and chemo-photothermal combination therapy. Nano Lett. 2019,19, 5806-5817. doi: 10.1021/acs.nanolett.9b02769 URL pmid: 31331172
29.	Li, Y.; Hu, H.; Zhou, Q.; Ao, Y.; Xiao, C.; Wan, J.; Wan, Y.; Xu, H.; Li, Z.; Yang, X. α-Amylase- and redox-responsive nanoparticles for tumor-targeted drug delivery. ACS Appl Mater Interfaces. 2017,9, 19215-19230. doi: 10.1021/acsami.7b04066 URL pmid: 28513132
30.	Hu, H.; Li, Y.; Zhou, Q.; Ao, Y.; Yu, C.; Wan, Y.; Xu, H.; Li, Z.; Yang, X. Redox-sensitive hydroxyethyl starch-doxorubicin conjugate for tumor targeted drug delivery. ACS Appl Mater Interfaces. 2016,8, 30833-30844. doi: 10.1021/acsami.6b11932 URL pmid: 27791359
31.	Hu, H.; Wan, J.; Huang, X.; Tang, Y.; Xiao, C.; Xu, H.; Yang, X.; Li, Z. iRGD-decorated reduction-responsive nanoclusters for targeted drug delivery. Nanoscale. 2018,10, 10514-10527. doi: 10.1039/c8nr02534g URL pmid: 29799599
32.	Xiao, C.; Hu, H.; Yang, H.; Li, S.; Zhou, H.; Ruan, J.; Zhu, Y.; Yang, X.; Li, Z. Colloidal hydroxyethyl starch for tumor-targeted platinum delivery. Nanoscale Adv. 2019,1, 1002-1012. doi: 10.1039/C8NA00271A URL
33.	Wu, H.; Hu, H.; Wan, J.; Li, Y.; Wu, Y.; Tang, Y.; Xiao, C.; Xu, H.; Yang, X.; Li, Z. Hydroxyethyl starch stabilized polydopamine nanoparticles for cancer chemotherapy. Chem Eng J. 2018,349, 129-145. doi: 10.1016/j.cej.2018.05.082 URL
34.	Liu, Q.; Yang, X.; Xu, H.; Pan, K.; Yang, Y. Novel nanomicelles originating from hydroxyethyl starch-g-polylactide and their release behavior of docetaxel modulated by the PLA chain length. Eur Polym J. 2013,49, 3522-3529. doi: 10.1016/j.eurpolymj.2013.08.012 URL
35.	Zhou, Q.; Li, Y.; Zhu, Y.; Yu, C.; Jia, H.; Bao, B.; Hu, H.; Xiao, C.; Zhang, J.; Zeng, X.; Wan, Y.; Xu, H.; Li, Z.; Yang, X. Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. J Control Release. 2018,275, 67-77. doi: 10.1016/j.jconrel.2018.02.026 URL pmid: 29471038
36.	Larson, N.; Ghandehari, H. Polymeric conjugates for drug delivery. Chem Mater. 2012,24, 840-853. doi: 10.1021/cm2031569 URL pmid: 22707853
37.	Zhou, P.; Li, Z.; Chau, Y. Synthesis, characterization, and in vivo evaluation of poly(ethylene oxide-co-glycidol)-platinate conjugate. Eur J Pharm Sci. 2010,41, 464-472. doi: 10.1016/j.ejps.2010.07.014 URL pmid: 20709170
38.	Lipinski, C. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev. 2002,5, 82-85.
39.	Zhu, C.; Liu, L.; Yang, Q.; Lv, F.; Wang, S. Water-soluble conjugated polymers for imaging, diagnosis, and therapy. Chem Rev. 2012,112, 4687-4735. doi: 10.1021/cr200263w URL pmid: 22670807
40.	Luo, Q.; Wang, P.; Miao, Y.; He, H.; Tang, X. A novel 5-fluorouracil prodrug using hydroxyethyl starch as a macromolecular carrier for sustained release. Carbohydr Polym. 2012,87, 2642-2647. doi: 10.1016/j.carbpol.2011.11.039 URL
41.	Zhou, Z.; Ma, X.; Jin, E.; Tang, J.; Sui, M.; Shen, Y.; Van Kirk, E. A.; Murdoch, W. J.; Radosz, M. Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery. Biomaterials. 2013,34, 5722-5735. doi: 10.1016/j.biomaterials.2013.04.012 URL pmid: 23639529
42.	Jana, S.; Mandlekar, S.; Marathe, P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Curr Med Chem. 2010,17, 3874-3908. doi: 10.2174/092986710793205426 URL pmid: 20858214
43.	Dong, Z.; Li, Q.; Guo, D.; Shu, Y.; Polli, J. E. Synjournal and evaluation of bile acid-ribavirin conjugates as prodrugs to target the liver. J Pharm Sci. 2015,104, 2864-2876. doi: 10.1002/jps.24375 URL pmid: 25645375
44.	Lelieveldt, L.; Kristyanto, H.; Pruijn, G. J. M.; Scherer, H. U.; Toes, R. E. M.; Bonger, K. M. Sequential prodrug strategy to target and eliminate ACPA-selective autoreactive B cells. Mol Pharm. 2018,15, 5565-5573. doi: 10.1021/acs.molpharmaceut.8b00741 URL pmid: 30289723
45.	Li, D.; Feng, X.; Chen, L.; Ding, J.; Chen, X. One-step synthesis of targeted acid-labile polysaccharide prodrug for efficiently intracellular drug delivery. ACS Biomater Sci Eng. 2018,4, 539-546. doi: 10.1021/acsbiomaterials.7b00856 URL
46.	Zhao, K.; Li, D.; Xu, W.; Ding, J.; Jiang, W.; Li, M.; Wang, C.; Chen, X. Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer. Biomaterials. 2017,116, 82-94. doi: 10.1016/j.biomaterials.2016.11.030 URL pmid: 27914269
47.	Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986,46, 6387-6392. URL pmid: 2946403
48.	Zhou, Q.; Shao, S.; Wang, J.; Xu, C.; Xiang, J.; Piao, Y.; Zhou, Z.; Yu, Q.; Tang, J.; Liu, X.; Gan, Z.; Mo, R.; Gu, Z.; Shen, Y. Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. Nat Nanotechnol. 2019,14, 799-809. doi: 10.1038/s41565-019-0485-z URL pmid: 31263194
49.	Li, G.; Li, Y.; Tang, Y.; Zhang, Y.; Zhang, Y.; Yin, T.; Xu, H.; Cai, C.; Tang, X. Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin. Int J Pharm. 2014,471, 234-244. doi: 10.1016/j.ijpharm.2014.05.038 URL pmid: 24861941
50.	Li, G.; Zhao, M.; Zhao, L. Well-defined hydroxyethyl starch-10-hydroxy camptothecin super macromolecule conjugate: cytotoxicity, pharmacodynamics research, tissue distribution test and intravenous injection safety assessment. Drug Deliv. 2016,23, 2860-2868. doi: 10.3109/10717544.2015.1110844 URL pmid: 26836216
51.	Zhu, Y.; Yao, X.; Chen, X.; Chen, L. pH-sensitive hydroxyethyl starch-doxorubicin conjugates as antitumor prodrugs with enhanced anticancer efficacy. J Appl Polym Sci. 2015,132, 42778.
52.	Sleightholm, R.; Yang, B.; Yu, F.; Xie, Y.; Oupický, D. Chloroquine-modified hydroxyethyl starch as a polymeric drug for cancer therapy. Biomacromolecules. 2017,18, 2247-2257. doi: 10.1021/acs.biomac.7b00023 URL pmid: 28708385
53.	Kuppusamy, P.; Li, H.; Ilangovan, G.; Cardounel, A. J.; Zweier, J. L.; Yamada, K.; Krishna, M. C.; Mitchell, J. B. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res. 2002,62, 307-312. URL pmid: 11782393
54.	Liu, S. V.; Liu, S.; Pinski, J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs. 2011,20, 769-778. URL pmid: 21449823
55.	Kunath, K.; von Harpe, A.; Fischer, D.; Kissel, T. Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J Control Release. 2003,88, 159-172. doi: 10.1016/s0168-3659(02)00458-3 URL pmid: 12586513
56.	Li, Y.; Liu, G.; Ma, J.; Lin, J.; Lin, H.; Su, G.; Chen, D.; Ye, S.; Chen, X.; Zhu, X.; Hou, Z. Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy. J Control Release. 2017,258, 95-107. doi: 10.1016/j.jconrel.2017.05.011 URL pmid: 28501673
57.	Yu, C.; Liu, C.; Wang, S.; Li, Z.; Hu, H.; Wan, Y.; Yang, X. Hydroxyethyl starch-based nanoparticles featured with redox-sensitivity and chemo-photothermal therapy for synergized tumor eradication. Cancers (Basel). 2019,11, 207. doi: 10.3390/cancers11020207 URL
58.	Hu, H.; Xiao, C.; Wu, H.; Li, Y.; Zhou, Q.; Tang, Y.; Yu, C.; Yang, X.; Li, Z. Nanocolloidosomes with selective drug release for active tumor-targeted imaging-guided photothermal/chemo combination therapy. ACS Appl Mater Interfaces. 2017,9, 42225-42238. doi: 10.1021/acsami.7b14796 URL pmid: 29124920
59.	Veronese, F. M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001,22, 405-417. doi: 10.1016/s0142-9612(00)00193-9 URL pmid: 11214751
60.	Nichols, J. W.; Bae, Y. H. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012,7, 606-618. doi: 10.1016/j.nantod.2012.10.010 URL pmid: 23243460
61.	Lemarchand, C.; Gref, R.; Couvreur, P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004,58, 327-341. doi: 10.1016/j.ejpb.2004.02.016 URL pmid: 15296959
62.	Baier, G.; Baumann, D.; Siebert, J. M.; Musyanovych, A.; Mailänder, V.; Landfester, K. Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch nanocapsules. Biomacromolecules. 2012,13, 2704-2715. doi: 10.1021/bm300653v URL pmid: 22844871
63.	Noga, M.; Edinger, D.; Kläger, R.; Wegner, S. V.; Spatz, J. P.; Wagner, E.; Winter, G.; Besheer, A. The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes. Biomaterials. 2013,34, 2530-2538. doi: 10.1016/j.biomaterials.2012.12.025 URL pmid: 23312901
64.	Liebner, R.; Mathaes, R.; Meyer, M.; Hey, T.; Winter, G.; Besheer, A. Protein HESylation for half-life extension: synjournal, characterization and pharmacokinetics of HESylated anakinra. Eur J Pharm Biopharm. 2014,87, 378-385. doi: 10.1016/j.ejpb.2014.03.010 URL pmid: 24681396
65.	Liu, Y.; Ai, K.; Lu, L. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields. Chem Rev. 2014,114, 5057-5115. doi: 10.1021/cr400407a URL pmid: 24517847
66.	Hu, H.; Chen, J.; Yang, H.; Huang, X.; Wu, H.; Wu, Y.; Li, F.; Yi, Y.; Xiao, C.; Li, Y.; Tang, Y.; Li, Z.; Zhang, B.; Yang, X. Potentiating photodynamic therapy of ICG-loaded nanoparticles by depleting GSH with PEITC. Nanoscale. 2019,11, 6384-6393. doi: 10.1039/c9nr01306g URL pmid: 30888375
67.	Jong, K.; Ju, B.; Zhang, S. Synjournal of pH-responsive N-acetyl-cysteine modified starch derivatives for oral delivery. J Biomater Sci Polym Ed. 2017,28, 1525-1537. doi: 10.1080/09205063.2017.1333698 URL pmid: 28532282
68.	Besheer, A.; Vogel, J.; Glanz, D.; Kressler, J.; Groth, T.; Mäder, K. Characterization of PLGA nanospheres stabilized with amphiphilic polymers: hydrophobically modified hydroxyethyl starch vs pluronics. Mol Pharm. 2009,6, 407-415. doi: 10.1021/mp800119h URL pmid: 19718794
69.	Chen, S.; Wu, J.; Tang, Q.; Xu, C.; Huang, Y.; Huang, D.; Luo, F.; Wu, Y.; Yan, F.; Weng, Z.; Wang, S. Nano-micelles based on hydroxyethyl starch-curcumin conjugates for improved stability, antioxidant and anticancer activity of curcumin. Carbohydr Polym. 2020,228, 115398. doi: 10.1016/j.carbpol.2019.115398 URL pmid: 31635734
70.	Naksuriya, O.; Okonogi, S.; Schiffelers, R. M.; Hennink, W. E. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014,35, 3365-3383. doi: 10.1016/j.biomaterials.2013.12.090 URL pmid: 24439402
71.	Serban, D.; Leng, J.; Cheresh, D. H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res. 2008,102, 1350-1358. doi: 10.1161/CIRCRESAHA.107.169664 URL pmid: 18467631
72.	Li, G.; Zhao, L. Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment. Drug Deliv. 2019,26, 756-764. doi: 10.1080/10717544.2019.1642418 URL pmid: 31357893
73.	Kang, B.; Okwieka, P.; Schöttler, S.; Seifert, O.; Kontermann, R. E.; Pfizenmaier, K.; Musyanovych, A.; Meyer, R.; Diken, M.; Sahin, U.; Mailänder, V.; Wurm, F. R.; Landfester, K. Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials. 2015,49, 125-134. URL pmid: 25725561

Name of prodrug	Name of drug	Responsiveness	Linkage	Strength	Reference
HES-SS-DOX	DOX	Redox	Disulphide bond	Responsive release; Improved efficiency; Reduced side effects	Hu et al.³⁰
HES-SS-PTX	PTX	Enzyme/Redox	Disulphide bond	Responsive release; Enhanced penetration; Improved efficiency; Reduced side effects	Li et al.²⁹
HES-FUAC	5-FU	-	Ester bond	Improved efficiency; Reduced side effects	Luo et al.⁴⁰
10-HCPT-HES	10-HCPT	-	Amide bond	Improved efficiency; Reduced side effects	Li et al.⁴⁹
HES-MTX	MTX	-	Ester bond	Improved efficiency; Reduced side effects	Goszczyński et al.¹⁷
CQ-HES	HCQ	-	Ester bond	Improved efficiency; Reduced side effects	Sleightholm et al.⁵²
HES-Hyd-DOX	DOX	pH	Hydrazine bond	Responsive release	Zhu et al.⁵¹
HES=DOX	DOX	pH	Imine bond	Targeting; Improved efficiency; Reduced side effects	Li et al.¹⁵
HES=DOX/cRGD	DOX	pH	Imine bond	Targeting; Improved efficiency; Reduced side effects	Li et al.⁴⁵
HES-DOX/LHRH	DOX	pH	Imine bond	Targeting; Improved efficiency; Reduced side effects	Zhao et al.⁴⁶
LA-HES-Pt	Pt	-	Ester bond	Improved efficiency; Reduced side effects	Xiao et al.³²

Name of prodrug	Name of drug	Responsiveness	Linkage	Strength	Reference
HES-SS-DOX	DOX	Redox	Disulphide bond	Responsive release; Improved efficiency; Reduced side effects	Hu et al.³⁰
HES-SS-PTX	PTX	Enzyme/Redox	Disulphide bond	Responsive release; Enhanced penetration; Improved efficiency; Reduced side effects	Li et al.²⁹
HES-FUAC	5-FU	-	Ester bond	Improved efficiency; Reduced side effects	Luo et al.⁴⁰
10-HCPT-HES	10-HCPT	-	Amide bond	Improved efficiency; Reduced side effects	Li et al.⁴⁹
HES-MTX	MTX	-	Ester bond	Improved efficiency; Reduced side effects	Goszczyński et al.¹⁷
CQ-HES	HCQ	-	Ester bond	Improved efficiency; Reduced side effects	Sleightholm et al.⁵²
HES-Hyd-DOX	DOX	pH	Hydrazine bond	Responsive release	Zhu et al.⁵¹
HES=DOX	DOX	pH	Imine bond	Targeting; Improved efficiency; Reduced side effects	Li et al.¹⁵
HES=DOX/cRGD	DOX	pH	Imine bond	Targeting; Improved efficiency; Reduced side effects	Li et al.⁴⁵
HES-DOX/LHRH	DOX	pH	Imine bond	Targeting; Improved efficiency; Reduced side effects	Zhao et al.⁴⁶
LA-HES-Pt	Pt	-	Ester bond	Improved efficiency; Reduced side effects	Xiao et al.³²

Name of nanoparticles	Name of drug	Responsiveness	Strength	Reference
DiR/HES-SS-PTX	PTX	Redox/Radiation	Combination therapy; Imaging	Li et al.²⁸
HES-SS-DOX@ICG	DOX	Redox/Radiation	Combination therapy; Imaging	Yu et al.⁵⁷
DOX@HES-g-PLA	DOX	-	RES blockade	Yu et al.²⁷
DOX/LY@HES-g-PLA	DOX	-	Overcoming metastasis	Zhou et al.³⁵
DOX/ICG@Gal-HES-PCL	DOX	Radiation	Targeting; Combination therapy; Imaging	Hu et al.⁵⁸
DOX@HES-PDA	DOX	-	HESylation comparison	Wu et al.³³
DOX@iRGD-HES-SS-C18	DOX	Redox	Targeting	Hu et al.³¹
ICG@HES-OA	PEITC	Radiation	Photodynamic therapy;Combination therapy	Hu et al.⁶⁶
PyHES-NAC	DOX	pH	Oral delivery	Jong et al.⁶⁷
HES-CUR	CUR	-	Improved efficiency	Chen et al.⁶⁹
HES-TG100-115-CDM-PEG	Sorafenib	-	Combination therapy	Li and Zhao⁷²

Name of nanoparticles	Name of drug	Responsiveness	Strength	Reference
DiR/HES-SS-PTX	PTX	Redox/Radiation	Combination therapy; Imaging	Li et al.²⁸
HES-SS-DOX@ICG	DOX	Redox/Radiation	Combination therapy; Imaging	Yu et al.⁵⁷
DOX@HES-g-PLA	DOX	-	RES blockade	Yu et al.²⁷
DOX/LY@HES-g-PLA	DOX	-	Overcoming metastasis	Zhou et al.³⁵
DOX/ICG@Gal-HES-PCL	DOX	Radiation	Targeting; Combination therapy; Imaging	Hu et al.⁵⁸
DOX@HES-PDA	DOX	-	HESylation comparison	Wu et al.³³
DOX@iRGD-HES-SS-C18	DOX	Redox	Targeting	Hu et al.³¹
ICG@HES-OA	PEITC	Radiation	Photodynamic therapy;Combination therapy	Hu et al.⁶⁶
PyHES-NAC	DOX	pH	Oral delivery	Jong et al.⁶⁷
HES-CUR	CUR	-	Improved efficiency	Chen et al.⁶⁹
HES-TG100-115-CDM-PEG	Sorafenib	-	Combination therapy	Li and Zhao⁷²

Hydroxyethyl starch and its derivatives as nanocarriers for delivery of diagnostic and therapeutic agents towards cancers

RichHTML

PDF

Knowledge

share this article

Abstract

Cite this article

Figures/Tables 10

References 73

Related Articles 0

Recommended Articles

Metrics

Comments

Journal Info

For Authors

For Reviewers

Archives